Originally developed as an antiparkinsonian drug [67], the MAO-B inhibitor deprenyl has been shown to have antidepressant effects in humans [68], [69], as well as rodents tested on traditional animal models of depression, including the forced swim test and inescapable shock paradigm [70], [71]. The gene discussed is MAOB; the disease is major depressive disorder.